Madrigal Pharmaceuticals Stock Revenue
| MDGL Stock | USD 355.88 46.39 14.99% |
Madrigal Pharmaceuticals fundamentals help investors to digest information that contributes to Madrigal Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Madrigal Stock. The fundamental analysis module provides a way to measure Madrigal Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Madrigal Pharmaceuticals stock.
Madrigal |
Madrigal Pharmaceuticals Company Revenue Analysis
Madrigal Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Madrigal Pharmaceuticals reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Madrigal Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Madrigal Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Madrigal Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Madrigal Pharmaceuticals by comparing valuation metrics of similar companies.Madrigal Pharmaceuticals is currently under evaluation in revenue category among its peers.
Madrigal Fundamentals
| Return On Equity | -1.3 | ||||
| Return On Asset | -0.52 | ||||
| Operating Margin | (1.87) % | ||||
| Current Valuation | 6.15 B | ||||
| Shares Outstanding | 21.81 M | ||||
| Shares Owned By Insiders | 8.70 % | ||||
| Shares Owned By Institutions | 91.30 % | ||||
| Number Of Shares Shorted | 3.98 M | ||||
| Price To Earning | (13.96) X | ||||
| Price To Book | 9.04 X | ||||
| Price To Sales | 91.47 X | ||||
| Gross Profit | 74.03 M | ||||
| EBITDA | (379.97 M) | ||||
| Net Income | (373.63 M) | ||||
| Cash And Equivalents | 211.77 M | ||||
| Cash Per Share | 12.38 X | ||||
| Total Debt | 117.19 M | ||||
| Debt To Equity | 0.59 % | ||||
| Current Ratio | 2.55 X | ||||
| Book Value Per Share | 35.64 X | ||||
| Cash Flow From Operations | (324.23 M) | ||||
| Short Ratio | 8.80 X | ||||
| Earnings Per Share | (25.03) X | ||||
| Target Price | 380.8 | ||||
| Number Of Employees | 376 | ||||
| Beta | -0.38 | ||||
| Market Capitalization | 7.03 B | ||||
| Total Asset | 640.55 M | ||||
| Retained Earnings | (1.34 B) | ||||
| Working Capital | 518.73 M | ||||
| Current Asset | 363.58 K | ||||
| Current Liabilities | 49.28 M | ||||
| Net Asset | 640.55 M |
About Madrigal Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Madrigal Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Madrigal Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Madrigal Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Madrigal Pharmaceuticals Piotroski F Score and Madrigal Pharmaceuticals Altman Z Score analysis. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.